1/8/2013

The FDA has approved a trial to assess a collection protocol for polymorphonuclear cells using the Spectra Optia platform, according to Terumo BCT. Polymorphonuclear cells from donors could help patients whose immune systems are compromised due to illness or chemotherapy.

Full Story:
InnovatioNews

Related Summaries